![Wills Hughes-Wilson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wills Hughes-Wilson
Corporate Officer/Principal bij
MEREO BIOPHARMA GROUP PLC
Vermogen: 16 051 $ op 30-06-2026
Profiel
Alexandra Hughes-Wilson is Chief Patient Access & Commercial Planning at Mereo BioPharma Group Plc since 2018.
Former roles include Chief Patient Access Officer & Senior VP at Swedish Orphan Biovitrum AB from 2016 to 2018, Executive Director at European Biopharmaceutical Enterprises, Vice President-Health & Market Access Policy at Genzyme Corp., and VP-Health & Market Access Policy EMEA at Genzyme Therapeutics Ltd. Education includes a graduate degree from the University of Durham.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-02-2026 | 252.375 ( 0,03% ) | 16 051 $ | 30-06-2026 |
Actieve functies van Wills Hughes-Wilson
| Bedrijven | Functie | Begin |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Corporate Officer/Principal | 01-03-2018 |
Eerdere bekende functies van Wills Hughes-Wilson
| Bedrijven | Functie | Einde |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Public Communications Contact | 01-01-2018 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | - |
European Biopharmaceutical Enterprises
 European Biopharmaceutical Enterprises BiotechnologyHealth Technology Develops biological products | Directeur/Bestuurslid | - |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | - |
Opleiding van Wills Hughes-Wilson
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
36
Eerstegraads connecties
6
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
University of Durham
 University of Durham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology Develops biological products | Health Technology |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Mereo BioPharma Group Plc
 Mereo BioPharma Group Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
